How is the therapeutic effect of osimertinib evaluated?

Osimertinib, as a third-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), has achieved significant clinical benefits in the treatment of non-small cell lung cancer(NSCLC) carrying EGFR mutations. According to data from multiple clinical studies, osimertinib has performed well in terms of response rate, progression-free survival, and overall survival. Specifically, the response rate of osimertinib can reach 55%-77%, and the progression-free survival can reach more than 19.3 months, or even longer in some studies. These data fully demonstrate the effectiveness of osimertinib in the treatment of patients with EGFR mutation-positive NSCLC.

Osimertinib can effectively penetrate the blood-brain barrier and also has a good therapeutic effect on intracranial metastases. Studies have shown that osimertinib is more effective in patients with non-small cell lung cancer who have brain metastases, which has greatly improved the quality of life and survival of patients.

Recent studies also show that the combination of osimertinib and chemotherapy can further extend the progression-free survival of patients. For example, in the FLAURA2 clinical trial, compared with osimertinib monotherapy, the global first-line standard treatment, the combination treatment regimen of osimertinib + chemotherapy can reduce the risk of disease progression or death, and the median progression-free survival has also been significantly prolonged. This discovery provides new treatment strategies for NSCLC patients.

In addition to common EGFR mutations, osimertinib also shows certain efficacy against rare EGFR mutations. For example, in the UNICORN study, the overall response rate of osimertinib in the first-line treatment of multiple rare EGFR mutations reached 55%, which provides a new treatment option for advanced patients with rare EGFR mutations.